Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3435922 | 0.95 | TSHR (0.65) | TSHRNOTUMALDH1A1NPC1RAB9A | |
| Acetamide SCHEMBL5312159 | 0.88 | TSHR (0.55) | TSHRNOTUMALDH1A1NPC1RAB9A | |
| Methacrylic Acid SCHEMBL8982198 | 0.87 | TSHR (0.48) | TSHRNOTUMALDH1A1NPC1RAB9A | |
| Hydrogen Peroxide SCHEMBL9391015 | 0.87 | TSHR (0.75) | TSHRALDH1A1NPC1RAB9AMEN1 | |
| Carbamic Acid SCHEMBL2175348 | 0.85 | TSHR (0.57) | TSHRNOTUMALDH1A1NPC1RAB9A | |
| Bicarbonate SCHEMBL28735118 | 0.84 | TSHR (0.72) | TSHRNOTUMALDH1A1NPC1RAB9A | |
| Butanone SCHEMBL7687029 | 0.84 | TSHR (0.50) | TSHRNOTUMALDH1A1NPC1RAB9A | |
| Methyl Alcohol SCHEMBL28873001 | 0.84 | TSHR (0.71) | TSHRNOTUMCYP2A6MAOAMAOB | |
| Benzene SCHEMBL27393093 | 0.84 | TSHR (0.80) | TSHRALDH1A1NPC1RAB9AMEN1 | |
| Urea SCHEMBL5312853 | 0.82 | TSHR (0.60) | TSHRNOTUMALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | claimed |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2018-07-19 | — | — | US | claimed |
| WO-2025054309-A9 | METHODS OF IDENTIFYING AND TREATING PATIENTS HAVING NEURODEGENERATIVE DISEASE BASED ON PLASMA BIOMARKER LEVELS | T3D THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025054309-A1 | METHODS OF IDENTIFYING AND TREATING PATIENTS HAVING NEURODEGENERATIVE DISEASE BASED ON PLASMA BIOMARKER LEVELS | T3D THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025024308-A1 | METHODS OF TREATING ENDOTHELIAL CELL AND AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025024308-A1 | METHODS OF TREATING ENDOTHELIAL CELL AND AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2023146818-A3 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC | 2003-11-20 | — | — | US | disclosed |
| WO-2003089418-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003089418-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003089418-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003011842-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011842-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011842-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-0034838-A3 | HALOGEN ETHYL ESTERS OF INDANE ACETIC ACID, AND THEIR PREPARATION | HEXACHIMIE Société anonyme dite: (FR) | 1981-10-07 | — | — | EP | disclosed |
| EP-0034838-A2 | Halogen ethyl esters of indane acetic acid, and their preparation | HEXACHIMIE Société anonyme dite: (FR) | 1981-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | TSHR 1452/4885NOTUM 2530/4885ALDH1A1 1138/4885 |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | TSHR 1452/4885NOTUM 2530/4885ALDH1A1 1138/4885 |
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | MAPT, APP, IAPP | TSHR 4137/4885NOTUM 2089/4885ALDH1A1 1679/4885 |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | TSHR 2926/4885NOTUM 157/4885ALDH1A1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.